CDTM Spinal System 510(k) Summary **February 7, 2000**

I. Company: Medtronic Sofamor Danek USA

1800 Pyramid Place Memphis, TN 38132 (901) 396-3133

Proposed Proprietary Trade Name: CDTM Spinal System II.

Product Description Ш.

The CDTM Spinal System consists of a variety of shapes and sizes of rods, hooks, screws, cross connectors, and connecting components. The components can be rigidly locked into a variety of configurations, with each construct tailor-made for the individual case.

The CDTM Spinal System implant components are fabricated from medical grade stainless steel described by such standards as ASTM F138 or its equivalent in ISO 5832-9. Alternatively, the entire system may be made out of medical grade titanium alloy described by such standards as ASTM F136 or its equivalent in ISO 5832-3.

The purpose of this 510(k) is to make the system available out of medical grade titanium alloy.

IV. **Indications**

When used as a pedicle screw fixation system of the non-cervical posterior spine in skeletally mature patients, the CDTM Spinal System is indicated for one or more of the following: (1) degenerative disc disease (as defined by back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies), (2) degenerative spondylolisthesis with objective evidence of neurologic impairment, (3) fracture, (4) dislocation, (5) scoliosis, (6) kyphosis, (7) spinal tumor, and/or (8) failed previous fusion (pseudarthrosis).

In addition, when used as a pedicle screw fixation system, the CDTM Spinal System is indicated for skeletally mature patients: (1) having severe spondylolisthesis (Grades 3 and 4) of the fifth lumbar-first sacral (L5-S1) vertebral joint; (2) who are receiving fusions using autogenous bone graft only; (3) who are having the device fixed or attached to the lumbar and sacral spine (L3 and below); and (4) who are having the device removed after the development of a solid fusion mass.

When used as a posterior, non-cervical, non-pedicle screw fixation system, the CDTM Spinal System is intended for the following indications: (1) degenerative disc disease (as defined by back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies), (2) spondylolisthesis, (3) fracture, (4) spinal deformities (i.e., scoliosis, kyphosis, and/or lordosis), (5) spinal stenosis, (6) pseudarthrosis, (7) tumor resection, and/or (8) failed previous fusion.

V. Substantial Equivalence

Documentation was provided which determined the CD™ Spinal System to be substantially equivalent to itself.

DEPARTMENT OF HEALTH & HUMAN SERVICES



MAR 1 0 2000

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Richard W. Treharne, Ph.D. Vice President Research and Regulatory Affairs Medtronic Sofamor Danek 1800 Pyramid Place Memphis, Tennessee 38132

Re: K000476

Trade Name: CD Spinal System

Regulatory Class: II

Product Code: MNH, MNI, KWP, KWQ

Dated: February 9, 2000 Received: February 14, 2000

Dear Dr. Treharne:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general control provisions of the Act. The general control provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the current Good Manufacturing Practice requirement, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic (QS) inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for <u>in vitro</u> diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597, or at its Internet address "http://www.fda.gov/cdrh/dsmamain.html".

Sincerely yours,

Sw James E. Dillard III

Acting Director

Division of General and

Restorative Devices

Office of Device Evaluation

Hundlyn

Center for Devices and Radiological Health

Enclosure

Indications for Use of Device Statement

510(k) Number	February 7, 2000
Device Name:_	CD TM Spinal System
Indications for	Jse:
mature degener disc cor with ob	d as a pedicle screw fixation system of the non-cervical posterior spine in skeletally tients, the CD TM Spinal System is indicated for one or more of the following: (1) we disc disease (as defined by back pain of discogenic origin with degeneration of the rmed by patient history and radiographic studies), (2) degenerative spondylolisthesistive evidence of neurologic impairment, (3) fracture, (4) dislocation, (5) scoliosis, (6) (7) spinal tumor, and/or (8) failed previous fusion (pseudarthrosis).
skeletal lumbar- graft on	n, when used as a pedicle screw fixation system the CD TM Spinal System is indicated for mature patients: (1) having severe spondylolisthesis (Grades 3 and 4) of the fifth st sacral (L5-S1) vertebral joint; (2) who are receiving fusions using autogenous bone (3) who are having the device fixed or attached to the lumbar and sacral spine (L3 and d (4) who are having the device removed after the development of a solid fusion mass.
System back pa radiogra kyphosi	d as a posterior, non-cervical, non-pedicle screw fixation system, the CD TM Spinal intended for the following indications: (1) degenerative disc disease (as defined by of discogenic origin with degeneration of the disc confirmed by patient history and its studies), (2) spondylolisthesis, (3) fracture, (4) spinal deformities (i.e., scoliosis and/or lordosis), (5) spinal stenosis, (6) pseudarthrosis, (7) tumor resection, and/or (8) ious fusion.
(PLEASE DO	OT WRITE BELOW THIS LINE—CONTINUE ON ANOTHER PAGE IF NEEDED)
	Concurrence of CDRH, Office of Evaluation (ODE)
Prescription Use (Per 21 CFR 801	OR Over-the-counter Use (Optional 1-2-96)
	Jamel / y
	(Division Sign-Off) Division of General Restorative Devices 510(k) Number